Recent Updates
Recently added Catalysts
FLNA Positive Sentiment

Cassava Announces Closure of U.S. Department of Justice Investigation

Thursday, February 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Cassava Sciences, Inc. has announced the closure of a U.S. Department of Justice investigation. This development is expected to positively impact the company's reputation and investor confidence. The company focuses on developing treatments for central nervous system disorders, including Tuberous Sclerosis Complex-related epilepsy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Closure of the investigation may enhance company reputation.
  • Potential for increased investor confidence.
  • Opportunity to refocus on product development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~62 mo
Minimal dilution risk
Lead asset
simufilam
Phase 3 · Alzheimer Disease

Full Press Release Details

AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy,

Frequently Asked Questions

What investigation was closed by Cassava Sciences?

Cassava Sciences announced the closure of a U.S. Department of Justice investigation.

How might the closure of the investigation affect Cassava?

The closure may enhance the company's reputation and increase investor confidence.

What is Cassava Sciences focused on developing?

Cassava Sciences focuses on investigational treatments for central nervous system disorders.

What specific disorder is mentioned in the article?

The article mentions Tuberous Sclerosis Complex-related epilepsy.

ShareAdd on Google
Tags: FLNA Cassava Sciences DOJ investigation CNS disorders Tuberous Sclerosis Complex
Last updated: Feb 19, 2026

Biotech snapshot

Cash runway
$83M liquidity · $1M/mo burn
~62 mo
Minimal dilution risk
Lead asset
simufilamPhase 3
Alzheimer Disease →